Navigation Links
Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
Date:8/13/2008

Orchid Pharma partners with Diakron

MORRIS PLAINS, N.J., Aug. 13 /PRNewswire/ -- Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

In a simultaneous transaction, Orchid Chemicals & Pharmaceuticals Ltd., the Chennai (India) based pharmaceutical major ("Orchid Pharma"), has signed an agreement to partner with Diakron as a significant shareholder and developer for the anticoagulant drug candidate. Orchid will be undertaking the next stages of development.

Announcing the successful conclusion of the agreements, Srirama Rao, PhD., a founder and the Chairman of Diakron said, "We are extremely pleased to be able to license this compound from Merck for further development and commercialization. We are also pleased that Orchid is partnering with us as a significant shareholder and developer of this compound, leveraging its world-class R&D infrastructure in India. This will allow Diakron to fast-track development of this unique anticoagulant product as its number one priority."

Commenting on the agreement, Dr. C.B. Rao, Deputy Managing Director of Orchid stated that partnering with Diakron for the development of this Merck compound is a significant development in Orchid's drug discovery journey. With its end-to-end drug discovery and drug development capability backed by US FDA and UK MHRA compliant manufacturing facilities, Orchid is well positioned to support the development of the compound all the way to successful commercialization, he observed.

"Despite recent advances there remains a significant unmet medical need for novel anticoagulant therapies," said Joseph Vacca, Executive Director of Medicinal Chemistry, External Basic Research at Merck & Co., Inc. "We believe that Diakron is well positioned to build on our early development work and, in collaboration with Orchid, spearhead the passage of this molecule through late stage clinical trials."

About Diakron Pharmaceuticals, Inc.

Diakron Pharmaceuticals, Inc. is a privately-owned pharmaceutical company specializing in the development of products for the treatment of certain cardiovascular diseases and diabetes.

About Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd. is a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well as in drug discovery. Orchid has research and manufacturing facilities aimed at global markets, thus emerging as a world-class pharmaceutical company covering the entire value chain from "Discovery to Delivery."

Contacts:

Diakron: Robert A. Anderson

Chief Marketing Officer

randerson@diakron.com

Orchid: C.B. Rao, PhD.

Deputy Managing Director

cbrao@orchidpharma.com


'/>"/>
SOURCE Diakron Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
4. Genetics Determine Optimal Drug Dose of Common Anticoagulant
5. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... Bill ... management industry in the coastal communities. After Tina Howe joined the team, the Bill ... happy employees, honest services at affordable rates, and giving back to the San Diego ...
Breaking Medicine News(10 mins):